Sominone

Sominone is the active metabolite of Withanoside IV (HY-N8693) . Sominone enhances neuronal morphological plasticity by activating the RET pathway. Sominone can also induce axon/dendrite regeneration and synaptic reconstruction, thereby improving spatial memory. Sominone can be used in the research of neurodegenerative diseases such as Alzheimer's disease[1][2][3].

Product Specifications

CAS Number

[98569-64-3]

UNSPSC

12352005

Target

Drug Metabolite; RET

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sominone.html

Purity

95.86

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@]3([H])[C@](CC=C1C[C@H](C[C@@H]2O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@@H]([C@@]5([H])CC(C)=C(C(O5)=O)CO)C)C

Molecular Formula

C28H42O5

Molecular Weight

458.63

References & Citations

[1]Kuboyama T, et al. Withanoside IV and its active metabolite, sominone, attenuate Abeta (25-35) -induced neurodegeneration. Eur J Neurosci. 2006 Mar;23 (6) :1417-26.|[2]Tohda C, et al. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET. Br J Pharmacol. 2009 Aug;157 (8) :1427-40.|[3]Joyashiki E, et al. Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. Int J Neurosci. 2011 Apr;121 (4) :181-90.